FAQ: The Medicare GLP-1 Bridge Program
CMS's Medicare GLP-1 Bridge launches July 1, giving eligible Part D beneficiaries access to branded obesity drugs at a $50 copay — outside the standard Part D benefit.
Despite reshaping obesity treatment, GLP-1 receptor agonists have remained out of reach for Medicare Part D beneficiaries seeking coverage for weight loss. Federal law prohibits Medicare from covering drugs solely for weight loss, meaning GLP-1s are only reimbursed under Part D for other approved indications, like type 2 diabetes, cardiovascular risk reduction, MASH, or sleep apnea.1 Despite these constraints, the commercial consequence has been significant: Medicare logged $27.5 billion in gross GLP-1 spending across 21.8 million claims in 2024, entirely under FDA-approved indications other than obesity.1 A new CMS demonstration is now attempting to expand that eligibility, at least temporarily.